0001179110-11-004058.txt : 20110303 0001179110-11-004058.hdr.sgml : 20110303 20110303163021 ACCESSION NUMBER: 0001179110-11-004058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110301 FILED AS OF DATE: 20110303 DATE AS OF CHANGE: 20110303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 45 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-274-8200 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rieder Wendy E CENTRAL INDEX KEY: 0001325714 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 11660645 MAIL ADDRESS: STREET 1: C/O SYNTA PHARMACEUTICALS CORP. STREET 2: 45 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 edgar.xml FORM 4 - X0303 4 2011-03-01 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001325714 Rieder Wendy E C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE LEXINGTON MA 02421 0 1 0 0 VP, IP and Legal, Gen. Counsel Common Stock 2011-03-01 4 S 0 5284 5.254 D 15426 D Common Stock 2011-03-01 4 A 0 4397 0 A 19823 D Employee Stock Option (Right to Buy) 5.26 2011-03-01 4 A 0 41891 0 A 2021-03-01 Common Stock 41891 41891 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2010, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2010. The shares were sold in multiple transactions at prices ranging from $5.25 to $5.33 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 100% of the shares on March 1, 2012, provided the Reporting Person remains employed by the Issuer on such date. The option vests as to 25% of the shares on March 1, 2012 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter. /s/ Ann Margaret Eames, Attorney-in-Fact 2011-03-03